Erratum: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv119-iv142) DOI: 10.1093/annonc/mdx225)

Ann Oncol 2017; 28: iv119-iv142 (doi:10.1093/annonc/mdx225) Under the section "Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Diagnosis" The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38]. Is replaced with: The sigmoid colon and the rectum are involved in most cases; therefore, a flexible sigmoidoscopy is generally sufficient to make the diagnosis of anti-CTLA4-induced enterocolitis [38, 42]. Under the section "Gastrointestinal toxicity: Gastrointestinal toxicity of anti-CTLA4 antibodies: Management" Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38]. Is replaced with: Overall, one-third to two-thirds of patients either do not respond to high-dose i.v. steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering [38, 42]. These patients require infliximab and usually have an excellent response. A single dose of infliximab (5mg/kg) is generally sufficient [18, 35, 36, 38, 42].